The Journal of Allergy and Clinical Immunology
Volume 118, Issue 3 , Pages 734-741, September 2006

Immunization with a low-dose replicon DNA vaccine encoding Phl p 5 effectively prevents allergic sensitization

  • Maximilian Gabler, PhD

      Affiliations

    • From the Christian Doppler Laboratory for Allergy Diagnostic and Therapy, Department of Molecular Biology, University of Salzburg
    • These authors contributed equally to this work.
  • ,
  • Sandra Scheiblhofer, PhD

      Affiliations

    • From the Christian Doppler Laboratory for Allergy Diagnostic and Therapy, Department of Molecular Biology, University of Salzburg
    • These authors contributed equally to this work.
  • ,
  • Kerstin Kern, MSc

      Affiliations

    • From the Christian Doppler Laboratory for Allergy Diagnostic and Therapy, Department of Molecular Biology, University of Salzburg
  • ,
  • Wolfgang W. Leitner, PhD

      Affiliations

    • Dermatology Branch, National Cancer Institute/National Institutes of Health, Bethesda
  • ,
  • Angelika Stoecklinger, MSc

      Affiliations

    • From the Christian Doppler Laboratory for Allergy Diagnostic and Therapy, Department of Molecular Biology, University of Salzburg
  • ,
  • Cornelia Hauser-Kronberger, PhD

      Affiliations

    • Department of Pathology, General Hospital and Paracelsus University Salzburg
  • ,
  • Beate Alinger, MSc

      Affiliations

    • Department of Pathology, General Hospital and Paracelsus University Salzburg
  • ,
  • Berta Lechner, MTA

      Affiliations

    • Department of Pathology, General Hospital and Paracelsus University Salzburg
  • ,
  • Monika Prinz, MTA

      Affiliations

    • Department of Pathology, General Hospital and Paracelsus University Salzburg
  • ,
  • Susanne Vrtala, PhD

      Affiliations

    • Department of Pathophysiology, Center for Physiology and Pathophysiology, the Medical University of Vienna
  • ,
  • Rudolf Valenta, MD

      Affiliations

    • Department of Pathophysiology, Center for Physiology and Pathophysiology, the Medical University of Vienna
  • ,
  • Josef Thalhamer, PhD

      Affiliations

    • From the Christian Doppler Laboratory for Allergy Diagnostic and Therapy, Department of Molecular Biology, University of Salzburg
    • Corresponding Author InformationReprint requests: Josef Thalhamer, PhD, University of Salzburg, Department of Molecular Biology, Division of Allergy and Immunology, Hellbrunnerstasse 34, 5020 Salzburg, Austria.
  • ,
  • Richard Weiss, PhD

      Affiliations

    • From the Christian Doppler Laboratory for Allergy Diagnostic and Therapy, Department of Molecular Biology, University of Salzburg

Received 22 July 2005; received in revised form 19 April 2006; accepted 27 April 2006. published online 05 June 2006.

Salzburg and Vienna, Austria, and Bethesda, Md

Background

Replicase-based DNA vaccines stimulate TH1-biased immune responses at ultralow doses and induce self-removal of transfected cells through apoptosis. Both aspects are important requirements for efficient and safe DNA-based immunotherapy of type I allergies.

Objective

A Sindbis virus replicon-based DNA vaccine encoding the major timothy grass pollen allergen Phl p 5 was evaluated for its antiallergic potential compared with a conventional DNA vaccine in a BALB/c mouse model of allergy.

Methods

Mice were intradermally prevaccinated with plasmid DNA, followed by sensitization and intranasal allergen provocation with recombinant Phl p 5. In vitro proliferation and cytokine secretion was measured in splenocyte cultures. Distribution of IgG1, IgG2a, and IgE antibody subclasses was determined by means of ELISA. IgE-mediated degranulation was measured with the basophil release assay. Bronchoalveolar lavage fluid was analyzed for eosinophils, IL-4, IL-5, IL-13, and IFN-γ. Mucus production, inflammatory infiltrates, and epithelial damage were determined in lung sections.

Results

Both vaccines induced TH1-biased immune responses, resulting in suppression of functional IgE, reduction of eosinophilia in bronchoalveolar lavage fluid, and alleviation of lung pathology. However, immunization with the replicon DNA vaccine elicited these effects at a 100-fold lower dose compared with the conventional DNA vaccine.

Conclusions

The increased immunogenicity of replicon-based DNA vaccines allows for application of extremely low doses, thereby eliminating the concerns associated with conventional DNA vaccines, which have to be administered at milligram amounts to induce immune reactions in human subjects.

Clinical implications

Their high safety profile makes replicon-based DNA vaccines promising candidates for treatment of type I allergies in the clinic.

Key words: Type I allergy, DNA vaccine, genetic immunization, replicase, alphavirus, Phl p 5, IgE, bronchoalveolar lavage, eosinophils, lung pathology

Abbreviations used: BAL, Bronchoalveolar lavage, H&E, Hematoxylin and eosin, PAS, Periodic acid–Schiff, pCMV, DNA expression vector without insert, pCMV-P5, DNA expression vector encoding Phl p 5, pSin, Sindbis replicon-based DNA expression vector without insert, pSin-P5, Sindbis replicon-based DNA expression vector encoding Phl p 5, TLR, Toll-like receptor

 

 Supported by the Austrian Science Foundation, project no. S8811, S8813, and T133-B08; the CeMM project of the Austrian Academy of Sciences; and the Ludwig Boltzmann Institute for Experimental Surgery.Disclosure of potential conflict of interest: The authors have declared that they have no conflict of interest.

PII: S0091-6749(06)00943-2

doi:10.1016/j.jaci.2006.04.048

The Journal of Allergy and Clinical Immunology
Volume 118, Issue 3 , Pages 734-741, September 2006